Investing
Acquired in-process research and development
Gilead Sciences Acquired in-process research and development increased by 217.6% to $540.00M in Q4 2025 compared to the prior quarter. Over 4 years (FY 2021 to FY 2025), Acquired in-process research and development shows an upward trend with a 55.1% CAGR. This is a positive signal — higher values indicate stronger performance for this metric.
Analysis
StatementCash Flow Statement
SectionInvesting
CategoryGrowth
SignalHigher is better
VolatilityVolatile
First reportedQ1 2013
Last reportedQ4 2025
How to read this metric
High spending indicates a strong commitment to pipeline growth, though it carries significant execution and regulatory risk.
Detailed definition
Acquired In-Process Research and Development (IPR&D) represents the cash paid to acquire research projects that have not...
Peer comparison
A hallmark metric for pharmaceutical and biotech firms relying on external innovation.
Metric ID:
cf_acquired_ipr_dHistorical Data
19 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $96.00M | $19.00M | $0.00 | $0.00 | $330.00M | $448.00M | $166.00M | $481.00M | $236.00M | $91.00M | $347.00M | $4.13B | $38.00M | $505.00M | $0.00 | $253.00M | $61.00M | $170.00M | $540.00M |
| QoQ Change | — | -80.2% | -100.0% | — | — | +35.8% | -62.9% | +189.8% | -50.9% | -61.4% | +281.3% | >999% | -99.1% | >999% | -100.0% | — | -75.9% | +178.7% | +217.6% |
| YoY Change | — | — | — | — | +243.8% | >999% | — | — | -28.5% | -79.7% | +109.0% | +758.8% | -83.9% | +454.9% | -100.0% | -93.9% | +60.5% | -66.3% | — |
Range$0.00 – $4.13B
CAGR+46.8%
Avg YoY Growth+286.1%
Median YoY Growth+16.0%
Current Streak2 quarters growth
Acquired in-process research and development at Other Companies
Frequently Asked Questions
- What is Gilead Sciences's acquired in-process research and development?
- Gilead Sciences (GILD) reported acquired in-process research and development of $540.00M in Q4 2025.
- What is the long-term trend for Gilead Sciences's acquired in-process research and development?
- Over 4 years (2021 to 2025), Gilead Sciences's acquired in-process research and development has grown at a 55.1% compound annual growth rate (CAGR), from $177.00M to $1.02B.
- What does acquired in-process research and development mean?
- Cash spent to buy research and development projects from other companies.